ZBTB7B and breast carcinoma: This therapeutic value might not be limited to breast cancer, since similar roles for ThPOK have been proposed in other cancers: in gastric cancer CTSLHigh/ZBTB7BLow expression marked poor outcomes [60], while in hepatocellular carcinoma, ZBTB7B loss promoted dedifferentiation and tumor initiation via c-Jun-mediated reprogramming [61].